Utility of large-scale transiently transfected cells for cell-based high-throughput screens to identify transient

Jun Chen1, Marc R Lake, Reza S Sabet

  • 1Neuroscience Research, Abbott Laboratories, Abbott Park, IL 60064-6125, USA. jun.x.chen@abbott.com

Insights

Large-scale transiently transfected (LSTT) cells offer a flexible and cost-effective solution for drug discovery. This method overcomes challenges with stable cell lines, enabling efficient screening for therapeutic targets like TRPA1.

Area of Science:

  • Pharmacology and Drug Discovery
  • Cell Biology and Assay Development

Background:

  • High-throughput screening (HTS) relies on robust cell-based assays, but challenges exist in obtaining consistent, high-quality cells expressing specific targets.
  • Stable cell lines, commonly used for target expression, often suffer from toxicity, degeneration, and loss of functional activity, particularly for targets like transient receptor potential A1 (TRPA1).

Purpose of the Study:

  • To develop a rapid and reliable method for establishing cell-based assays suitable for HTS, specifically for identifying TRPA1 antagonists.
  • To circumvent the limitations associated with stable cell line expression for pharmaceutical target research.

Main Methods:

  • Utilized large-scale transiently transfected (LSTT) cells for target expression, enabling rapid assay establishment.
  • Developed a method for long-term frozen storage (≥42 weeks) of LSTT cells while maintaining target protein expression and functionality.
  • Screened a chemical library of 700,000 compounds using revived LSTT cells in calcium influx and electrophysiological assays.

Main Results:

  • LSTT cells retained TRPA1 protein expression and provided robust, consistent signals after long-term storage and revival.
  • Successful identification of TRPA1 antagonists through screening of a large compound library using LSTT cells.
  • Demonstrated increased flexibility, consistency, and significant reductions in labor and cost compared to traditional stable cell line methods.

Conclusions:

  • Large-scale transiently transfected cells provide a viable and advantageous alternative to stable cell lines for drug discovery assays.
  • This LSTT approach effectively addresses challenges in cell culture, expression variability, and target activity, offering a scalable solution.
  • The methodology is broadly applicable to other pharmaceutical targets beyond TRPA1, enhancing efficiency in drug development pipelines.